Biomarkers in amyotrophic lateral sclerosis

The Lancet Neurology

Volumn 8, Issue 1, 2009, Pages 94-109

  Turner, Martin R ^a,b   Kiernan, Matthew C ^c   Leigh, P Nigel ^d   Talbot, Kevin ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYNONENAL; ANGIOGENIN; BIOLOGICAL MARKER; CREATINE; ERYTHROPOIETIN; FIBRONECTIN; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLUTAMIC ACID; HIGH DENSITY LIPOPROTEIN; HYALURONIC ACID; INTERLEUKIN 13; INTERLEUKIN 6; LEUCINE; LOW DENSITY LIPOPROTEIN; LYSINE; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 1 ALPHA; NEUROFILAMENT PROTEIN; PROTEIN NOGO A; RILUZOLE; SOMATOMEDIN; SUBSTANCE P; TRANSFORMING GROWTH FACTOR BETA1; TYROSINE; UNCLASSIFIED DRUG; VASCULOTROPIN;

AMYOTROPHIC LATERAL SCLEROSIS; BLOOD ANALYSIS; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID LEVEL; DISEASE MARKER; DRUG MECHANISM; HUMAN; MAGNETOENCEPHALOGRAPHY; MOTONEURON; MUSCLE BIOPSY; NEUROPHYSIOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; TRANSCRANIAL MAGNETIC STIMULATION;

AMYOTROPHIC LATERAL SCLEROSIS; BIOLOGICAL MARKERS; BRAIN CHEMISTRY; DISEASE PROGRESSION; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; PHENOTYPE;

EID: 57149120501     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(08)70293-X     Document Type: Review

References (131)

1. Beghi E., Logroscino G., Chio A., et al. The epidemiology of ALS and the role of population-based registries. Biochim Biophys Acta 1762 (2006) 1150-1157
2. Liscic R.M., Grinberg L.T., Zidar J., Gitcho M.A., and Cairns N.J. ALS and FTLD: two faces of TDP-43 proteinopathy. Eur J Neurol 15 (2008) 772-780
3. De Vos K.J., Grierson A.J., Ackerley S., and Miller C.C. Role of axonal transport in neurodegenerative diseases. Ann Rev Neurosci 31 (2008) 151-173
4. Shaw P.J. Molecular and cellular pathways of neurodegeneration in motor neurone disease. J Neurol Neurosurg Psychiatry 76 (2005) 1046-1057
5. Schymick J.C., Scholz S.W., Fung H.C., et al. Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls: first stage analysis and public release of data. Lancet Neurol 6 (2007) 322-328
6. Schymick J.C., Talbot K., and Traynor B.J. Genetics of sporadic amyotrophic lateral sclerosis. Hum Mol Genet 16 (2007) R233-R242
7. Brooks B.R., Miller R.G., Swash M., and Munsat T.L. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 1 (2000) 293-299
8. Ravits J., Paul P., and Jorg C. Focality of upper and lower motor neuron degeneration at the clinical onset of ALS. Neurology 68 (2007) 1571-1575
9. Ravits J., Laurie P., Fan Y., and Moore D.H. Implications of ALS focality: rostral-caudal distribution of lower motor neuron loss postmortem. Neurology 68 (2007) 1576-1582
10. de Carvalho M., Dengler R., Eisen A., et al. Electrodiagnostic criteria for diagnosis of ALS. Clin Neurophysiol 119 (2008) 497-503
11. Zoccolella S., Beghi E., Palagano G., et al. Predictors of delay in the diagnosis and clinical trial entry of amyotrophic lateral sclerosis patients: a population-based study. J Neurol Sci 250 (2006) 45-49
12. Swash M., and Ingram D. Preclinical and subclinical events in motor neuron disease. J Neurol Neurosurg Psychiatry 51 (1988) 165-168
13. Turner M.R., and Al Chalabi A. Clinical phenotypes. In: Kiernan M.C. (Ed). The Motor Neurone Disease Handbook (2007), Australian Medical Publishing Company, Sydney 55-73
14. Turner M.R., Parton M.J., Shaw C.E., Leigh P.N., and Al Chalabi A. Prolonged survival in motor neuron disease: a descriptive study of the King's database 1990-2002. J Neurol Neurosurg Psychiatry 74 (2003) 995-997
15. Hu M.T., Ellis C.M., Al Chalabi A., Leigh P.N., and Shaw C.E. Flail arm syndrome: a distinctive variant of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 65 (1998) 950-951
16. Vucic S., and Kiernan M.C. Abnormalities in cortical and peripheral excitability in flail arm variant amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 78 (2007) 849-852
17. de Carvalho M., Matias T., Coelho F., Evangelista T., Pinto A., and Luis M.L. Motor neuron disease presenting with respiratory failure. J Neurol Sci 139 (1996) 117-122
18. Shoesmith C.L., Findlater K., Rowe A., and Strong M.J. Prognosis of amyotrophic lateral sclerosis with respiratory onset. J Neurol Neurosurg Psychiatry 78 (2007) 629-631
19. Leigh P.N., Abrahams S., Al Chalabi A., et al. The management of motor neurone disease. J Neurol Neurosurg Psychiatry 74 (2003) 32-47
20. Lacomblez L., Bensimon G., Leigh P.N., Guillet P., and Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 347 (1996) 1425-1431
21. Turner B.J., and Talbot K. Transgenics, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS. Prog Neurobiol 85 (2008) 94-134
22. Scott S., Kranz J.E., Cole J., et al. Design, power, and interpretation of studies in the standard murine model of ALS. Amyotroph Lateral Scler 9 (2008) 4-15
23. Ludolph A.C., Bendotti C., Blaugrund E., et al. Guidelines for the preclinical in vivo evaluation of pharmacological active drugs for ALS/MND: report on the 142nd ENMC international workshop. Amyotroph Lateral Scler 8 (2007) 217-223
24. Winhammar J.M., Rowe D.B., Henderson R.D., and Kiernan M.C. Assessment of disease progression in motor neuron disease. Lancet Neurol 4 (2005) 229-238
25. Ryberg H., and Bowser R. Protein biomarkers for amyotrophic lateral sclerosis. Expert Rev Proteomics 5 (2008) 249-262
26. Patten B.M., Harati Y., Acosta L., Jung S.S., and Felmus M.T. Free amino acid levels in amyotrophic lateral sclerosis. Ann Neurol 3 (1978) 305-309
27. Camu W., Billiard M., and Baldy-Moulinier M. Fasting plasma and CSF amino acid levels in amyotrophic lateral sclerosis: a subtype analysis. Acta Neurol Scand 88 (1993) 51-55
28. Ilzecka J., Stelmasiak Z., Solski J., Wawrzycki S., and Szpetnar M. Plasma amino acids percentages in amyotrophic lateral sclerosis patients. Neurol Sci 24 (2003) 293-295
29. Ono S., Imai T., Shimizu N., et al. Decreased plasma levels of fibronectin in amyotrophic lateral sclerosis. Acta Neurol Scand 101 (2000) 391-394
30. Ono S., Imai T., Tsumura M., et al. Increased serum hyaluronic acid in amyotrophic lateral sclerosis: relation to its skin content. Amyotroph Lateral Scler Other Motor Neuron Disord 1 (2000) 213-218
31. Ono S., Hu J., Shimizu N., Imai T., and Nakagawa H. Increased interleukin-6 of skin and serum in amyotrophic lateral sclerosis. J Neurol Sci 187 (2001) 27-34
32. Houi K., Kobayashi T., Kato S., Mochio S., and Inoue K. Increased plasma TGF-beta1 in patients with amyotrophic lateral sclerosis. Acta Neurol Scand 106 (2002) 299-301
33. Simpson E.P., Henry Y.K., Henkel J.S., Smith R.G., and Appel S.H. Increased lipid peroxidation in sera of ALS patients: a potential biomarker of disease burden. Neurology 62 (2004) 1758-1765
34. Cronin S., Greenway M.J., Ennis S., et al. Elevated serum angiogenin levels in ALS. Neurology 67 (2006) 1833-1836
35. Shi N., Kawano Y., Tateishi T., et al. Increased IL-13-producing T cells in ALS: positive correlations with disease severity and progression rate. J Neuroimmunol 182 (2007) 232-235
36. Hosback S., Hardiman O., Nolan C.M., et al. Circulating insulin-like growth factors and related binding proteins are selectively altered in amyotrophic lateral sclerosis and multiple sclerosis. Growth Horm IGF Res 17 (2007) 472-479
37. Dupuis L., Corcia P., Fergani A., et al. Dyslipidemia is a protective factor in amyotrophic lateral sclerosis. Neurology 70 (2008) 1004-1009
38. Kolde G., Bachus R., and Ludolph A.C. Skin involvement in amyotrophic lateral sclerosis. Lancet 347 (1996) 1226-1227
39. Neumann M., Sampathu D.M., Kwong L.K., et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314 (2006) 130-133
40. Foulds P., McAuley E., Gibbons L., et al. TDP-43 protein in plasma may index TDP-43 brain pathology in Alzheimer's disease and frontotemporal lobar degeneration. Acta Neuropathol 116 (2008) 141-146
41. Ince P.G., Evans J., Knopp M., et al. Corticospinal tract degeneration in the progressive muscular atrophy variant of ALS. Neurology 60 (2003) 1252-1258
42. Peskind E.R., Riekse R., Quinn J.F., et al. Safety and acceptability of the research lumbar puncture. Alzheimer Dis Assoc Disord 19 (2005) 220-225
43. Rosengren L.E., Karlsson J.E., Karlsson J.O., Persson L.I., and Wikkelso C. Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J Neurochem 67 (1996) 2013-2018
44. Brettschneider J., Petzold A., Sussmuth S.D., Ludolph A.C., and Tumani H. Axonal damage markers in cerebrospinal fluid are increased in ALS. Neurology 66 (2006) 852-856
45. Zetterberg H., Jacobsson J., Rosengren L., Blennow K., and Andersen P.M. Cerebrospinal fluid neurofilament light levels in amyotrophic lateral sclerosis: impact of SOD1 genotype. Eur J Neurol 14 (2007) 1329-1333
46. Matsuishi T., Nagamitsu S., Shoji H., et al. Increased cerebrospinal fluid levels of substance P in patients with amyotrophic lateral sclerosis. Short communication. J Neural Transm 106 (1999) 943-948
47. Grundstrom E., Lindholm D., Johansson A., Blennow K., and Askmark H. GDNF but not BDNF is increased in cerebrospinal fluid in amyotrophic lateral sclerosis. Neuroreport 11 (2000) 1781-1783
48. Tanaka M., Kikuchi H., Ishizu T., et al. Intrathecal upregulation of granulocyte colony stimulating factor and its neuroprotective actions on motor neurons in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 65 (2006) 816-825
49. Moreau C., Devos D., Brunaud-Danel V., et al. Paradoxical response of VEGF expression to hypoxia in CSF of patients with ALS. J Neurol Neurosurg Psychiatry 77 (2006) 255-257
50. Brettschneider J., Widl K., Schattauer D., Ludolph A.C., and Tumani H. Cerebrospinal fluid erythropoietin (EPO) in amyotrophic lateral sclerosis. Neurosci Lett 416 (2007) 257-260
51. Siciliano G., Piazza S., Carlesi C., et al. Antioxidant capacity and protein oxidation in cerebrospinal fluid of amyotrophic lateral sclerosis. J Neurol 254 (2007) 575-580
52. Rothstein J.D., Tsai G., Kuncl R.W., et al. Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann Neurol 28 (1990) 18-25
53. Oosthuyse B., Moons L., Storkebaum E., et al. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet 28 (2001) 131-138
54. Dietl M.M., Sanchez M., Probst A., and Palacios J.M. Substance P receptors in the human spinal cord: decrease in amyotrophic lateral sclerosis. Brain Res 483 (1989) 39-49
55. Ranganathan S., Williams E., Ganchev P., et al. Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosis. J Neurochem 95 (2005) 1461-1471
56. Pasinetti G.M., Ungar L.H., Lange D.J., et al. Identification of potential CSF biomarkers in ALS. Neurology 66 (2006) 1218-1222
57. Ranganathan S., Nicholl G.C., Henry S., et al. Comparative proteomic profiling of cerebrospinal fluid between living and post mortem ALS and control subjects. Amyotroph Lateral Scler 8 (2007) 373-379
58. Waragai M., Shinotoh H., Hayashi M., and Hattori T. High signal intensity on T1-weighted MRI of the anterolateral column of the spinal cord in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 62 (1997) 88-91
59. Waragai M. MRI and clinical features in amyotrophic lateral sclerosis. Neuroradiology 39 (1997) 847-851
60. Peretti-Viton P., Azulay J.P., Trefouret S., et al. MRI of the intracranial corticospinal tracts in amyotrophic and primary lateral sclerosis. Neuroradiology 41 (1999) 744-749
61. Pioro E.P., Antel J.P., Cashman N.R., and Arnold D.L. Detection of cortical neuron loss in motor neuron disease by proton magnetic resonance spectroscopic imaging in vivo. Neurology 44 (1994) 1933-1938
62. Gredal O., Rosenbaum S., Topp S., Karlsborg M., Strange P., and Werdelin L. Quantification of brain metabolites in amyotrophic lateral sclerosis by localized proton magnetic resonance spectroscopy. Neurology 48 (1997) 878-881
63. Pioro E.P., Majors A.W., Mitsumoto H., Nelson D.R., and Ng T.C. 1H-MRS evidence of neurodegeneration and excess glutamate+glutamine in ALS medulla. Neurology 53 (1999) 71-79
64. Cwik V.A., Hanstock C.C., Allen P.S., and Martin W.R. Estimation of brainstem neuronal loss in amyotrophic lateral sclerosis with in vivo proton magnetic resonance spectroscopy. Neurology 50 (1998) 72-77
65. Wang S., Poptani H., Woo J.H., et al. Amyotrophic lateral sclerosis: diffusion-tensor and chemical shift MR imaging at 3.0 T. Radiology 239 (2006) 831-838
66. Sarchielli P., Pelliccioli G.P., Tarducci R., et al. Magnetic resonance imaging and 1H-magnetic resonance spectroscopy in amyotrophic lateral sclerosis. Neuroradiology 43 (2001) 189-197
67. Pohl C., Block W., Karitzky J., et al. Proton magnetic resonance spectroscopy of the motor cortex in 70 patients with amyotrophic lateral sclerosis. ArchNeurol 58 (2001) 729-735
68. Suhy J., Miller R.G., Rule R., et al. Early detection and longitudinal changes in amyotrophic lateral sclerosis by (1)H MRSI. Neurology 58 (2002) 773-779
69. Kalra S., Cashman N.R., Caramanos Z., Genge A., and Arnold D.L. Gabapentin therapy for amyotrophic lateral sclerosis: lack of improvement in neuronal integrity shown by MR spectroscopy. AJNR AmJ Neuroradiol 24 (2003) 476-480
70. Kalra S., Tai P., Genge A., and Arnold D.L. Rapid improvement in cortical neuronal integrity in amyotrophic lateral sclerosis detected by proton magnetic resonance spectroscopic imaging. J Neurol 253 (2006) 1060-1063
71. Ellis C.M., Simmons A., Jones D.K., et al. Diffusion tensor MRI assesses corticospinal tract damage in ALS. Neurology 53 (1999) 1051-1058
72. Cosottini M., Giannelli M., Siciliano G., et al. Diffusion-tensor MR imaging of corticospinal tract in amyotrophic lateral sclerosis and progressive muscular atrophy. Radiology 237 (2005) 258-264
73. Aoki S., Iwata N.K., Masutani Y., et al. Quantitative evaluation of the pyramidal tract segmented by diffusion tensor tractography: feasibility study in patients with amyotrophic lateral sclerosis. Radiat Med 23 (2005) 195-199
74. Ciccarelli O., Behrens T.E., Altmann D.R., et al. Probabilistic diffusion tractography: a potential tool to assess the rate of disease progression in amyotrophic lateral sclerosis. Brain 129 (2006) 1859-1871
75. Wong J.C., Concha L., Beaulieu C., Johnston W., Allen P.S., and Kalra S. Spatial profiling of the corticospinal tract in amyotrophic lateral sclerosis using diffusion tensor imaging. J Neuroimaging 17 (2007) 234-240
76. Roccatagliata L., Bonzano L., Mancardi G., Canepa C., and Caponnetto C. Detection of motor cortex thinning and corticospinal tract involvement by quantitative MRI in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 11 (2008) 1-6
77. Sach M., Winkler G., Glauche V., et al. Diffusion tensor MRI of early upper motor neuron involvement in amyotrophic lateral sclerosis. Brain 127 (2004) 340-350
78. Iwata N.K., Aoki S., Okabe S., et al. Evaluation of corticospinal tracts in ALS with diffusion tensor MRI and brainstem stimulation. Neurology 70 (2008) 528-532
79. Hong Y.H., Lee K.W., Sung J.J., Chang K.H., and Song I.C. Diffusion tensor MRI as a diagnostic tool of upper motor neuron involvement in amyotrophic lateral sclerosis. J Neurol Sci 227 (2004) 73-78
80. Ciccarelli O., Behrens T.E., Johansen-Berg H., et al. Investigation of white matter pathology in ALS and PLS using tract-based spatial statistics. Hum Brain Mapp (2008) 10.1002/hbm.20527 published online Jan 2.
81. Bartels C., Mertens N., Hofer S., et al. Callosal dysfunction in amyotrophic lateral sclerosis correlates with diffusion tensor imaging of the central motor system. Neuromuscul Disord 18 (2008) 398-407
82. Sage C.A., Peeters R.R., Gorner A., Robberecht W., and Sunaert S. Quantitative diffusion tensor imaging in amyotrophic lateral sclerosis. Neuroimage 34 (2007) 486-499
83. Valsasina P., Agosta F., Benedetti B., et al. Diffusion anisotropy of the cervical cord is strictly associated with disability in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 78 (2007) 480-484
84. Stanton BR, Shinhmar D, Turner MR, et al. Diffusion tensor imaging in sporadic and familial (D90A SOD1) forms of amyotrophic lateral sclerosis. Arch Neurol (in press).
85. Abrahams S., Goldstein L.H., Suckling J., et al. Frontotemporal white matter changes in amyotrophic lateral sclerosis. J Neurol 252 (2005) 321-331
86. Chang J.L., Lomen-Hoerth C., Murphy J., et al. A voxel-based morphometry study of patterns of brain atrophy in ALS and ALS/FTLD. Neurology 65 (2005) 75-80
87. Grosskreutz J., Kaufmann J., Fradrich J., Dengler R., Heinze H.J., and Peschel T. Widespread sensorimotor and frontal cortical atrophy in amyotrophic lateral sclerosis. BMC Neurol 6 (2006) 17
88. Turner M.R., Hammers A., Allsop J., et al. Volumetric cortical loss in sporadic and familial amyotrophic lateral sclerosis. Amyotroph Lateral Scler 8 (2007) 343-347
89. Tessitore A., Esposito F., Monsurro M.R., et al. Subcortical motor plasticity in patients with sporadic ALS: an fMRI study. Brain Res Bull 69 (2006) 489-494
90. Lule D., Diekmann V., Kassubek J., et al. Cortical plasticity in amyotrophic lateral sclerosis: motor imagery and function. Neurorehabil Neural Repair 21 (2007) 518-526
91. Boyajian R.A., Amo C., Otis S.M., Romine J.S., and Smith R.A. Magnetic source imaging of cortical dysfunction in amyotrophic lateral sclerosis. Am J Phys Med Rehabil 87 (2008) 427-437
92. Iwasaki Y., Kinoshita M., Ikeda K., Takamiya K., and Shiojima T. MRI in patients with amyotrophic lateral sclerosis: correlation with clinical features. Int J Neurosci 59 (1991) 253-258
93. Turner M.R. Reversible diffusion MRI abnormalities and transient mutism after liver transplantation. Neurology 64 (2005) 177
94. Kalra S., Cashman N.R., Genge A., and Arnold D.L. Recovery of N-acetylaspartate in corticomotor neurons of patients with ALS after riluzole therapy. Neuroreport 9 (1998) 1757-1761
95. Beaulieu C. The basis of anisotropic water diffusion in the nervous system-a technical review. NMR Biomed 15 (2002) 435-455
96. Ciccarelli O., Catani M., Johansen-Berg H., Clark C., and Thompson A. Diffusion-based tractography in neurological disorders: concepts, applications, and future developments. Lancet Neurol 7 (2008) 715-727
97. Turner M.R., Hammers A., Al-Chalabi A., et al. Cortical involvement in four cases of primary lateral sclerosis using [(11)C]-flumazenil PET. J Neurol 254 (2007) 1033-1036
98. Andersen P.M., Forsgren L., Binzer M., et al. Autosomal recessive adult-onset amyotrophic lateral sclerosis associated with homozygosity for Asp90Ala CuZn-superoxide dismutase mutation. A clinical and genealogical study of 36 patients. Brain 119 (1996) 1153-1172
99. Ng M.C., Ho J.T., Ho S.L., et al. Abnormal diffusion tensor in nonsymptomatic familial amyotrophic lateral sclerosis with a causative superoxide dismutase 1 mutation. J Magn Reson Imaging 27 (2008) 8-13
100. Ashburner J., and Friston K.J. Voxel-based morphometry-the methods. Neuroimage 11 (2000) 805-821
101. Vucic S., and Kiernan M.C. Novel threshold tracking techniques suggest that cortical hyperexcitability is an early feature of motor neuron disease. Brain 129 (2006) 2436-2446
102. Yokota T., Yoshino A., Inaba A., and Saito Y. Double cortical stimulation in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 61 (1996) 596-600
103. Ziemann U., Winter M., Reimers C.D., Reimers K., Tergau F., and Paulus W. Impaired motor cortex inhibition in patients with amyotrophic lateral sclerosis. Evidence from paired transcranial magnetic stimulation. Neurology 49 (1997) 1292-1298
104. Stefan K., Kunesch E., Benecke R., and Classen J. Effects of riluzole on cortical excitability in patients with amyotrophic lateral sclerosis. Ann Neurol 49 (2001) 536-539
105. Ziemann U. TMS and drugs. Clin Neurophysiol 115 (2004) 1717-1729
106. Chen R., Lozano A.M., and Ashby P. Mechanism of the silent period following transcranial magnetic stimulation. Evidence from epidural recordings. Exp Brain Res 128 (1999) 539-542
107. Werhahn K.J., Kunesch E., Noachtar S., Benecke R., and Classen J. Differential effects on motorcortical inhibition induced by blockade of GABA uptake in humans. J Physiol 517 (1999) 591-597
108. Raynor E.M., and Shefner J.M. Recurrent inhibition is decreased in patients with amyotrophic lateral sclerosis. Neurology 44 (1994) 2148-2153
109. Drory V.E., Kovach I., and Groozman G.B. Electrophysiologic evaluation of upper motor neuron involvement in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2 (2001) 147-152
110. Zanette G., Tamburin S., Manganotti P., Refatti N., Forgione A., and Rizzuto N. Changes in motor cortex inhibition over time in patients with amyotrophic lateral sclerosis. J Neurol 249 (2002) 1723-1728
111. Vucic S., Nicholson G.A., and Kiernan M.C. Cortical hyperexcitability may precede the onset of familial amyotrophic lateral sclerosis. Brain 131 (2008) 1540-1550
112. Turner M.R., Hammers A., Al Chalabi A., et al. Distinct cerebral lesions in sporadic and 'D90A' SOD1 ALS: studies with [11C]flumazenil PET. Brain 128 (2005) 1323-1329
113. Vucic S., and Kiernan M.C. Cortical excitability testing distinguishes Kennedy's disease from amyotrophic lateral sclerosis. Clin Neurophysiol 119 (2008) 1088-1096
114. Shefner J.M. Motor unit number estimation in human neurological diseases and animal models. Clin Neurophysiol 112 (2001) 955-964
115. Lomen-Hoerth C., and Slawnych M.P. Statistical motor unit number estimation: from theory to practice. Muscle Nerve 28 (2003) 263-272
116. Henderson R.D., McClelland R., and Daube J.R. Effect of changing data collection parameters on statistical motor unit number estimates. Muscle Nerve 27 (2003) 320-331
117. Shefner J.M., Cudkowicz M.E., Zhang H., Schoenfeld D., and Jillapalli D. The use of statistical MUNE in a multicenter clinical trial. Muscle Nerve 30 (2004) 463-469
118. Aggarwal A., and Nicholson G. Detection of preclinical motor neurone loss in SOD1 mutation carriers using motor unit number estimation. J Neurol Neurosurg Psychiatry 73 (2002) 199-201
119. Henderson R.D., Ridall P.G., Hutchinson N.M., Pettitt A.N., and McCombe P.A. Bayesian statistical MUNE method. Muscle Nerve 36 (2007) 206-213
120. Burke D., Kiernan M.C., and Bostock H. Excitability of human axons. Clin Neurophysiol 112 (2001) 1575-1585
121. Mogyoros I., Kiernan M.C., Burke D., and Bostock H. Strength-duration properties of sensory and motor axons in amyotrophic lateral sclerosis. Brain 121 (1998) 851-859
122. Kanai K., Kuwabara S., Misawa S., et al. Altered axonal excitability properties in amyotrophic lateral sclerosis: impaired potassium channel function related to disease stage. Brain 129 (2006) 953-962
123. Nakata M., Kuwabara S., Kanai K., et al. Distal excitability changes in motor axons in amyotrophic lateral sclerosis. Clin Neurophysiol 117 (2006) 1444-1448
124. Vucic S., and Kiernan M.C. Axonal excitability properties in amyotrophic lateral sclerosis. Clin Neurophysiol 117 (2006) 1458-1466
125. Kiernan M.C., and Burke D. Threshold electrotonus in the assessment of motor neuron disease. In: Eisen A. (Ed). Clinical Neurophysiology of Motor Neuron Diseases (2004), Elsevier, Amsterdam 359-366
126. Vucic S., Krishnan A.V., and Kiernan M.C. Fatigue and activity dependent changes in axonal excitability in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 78 (2007) 1202-1208
127. Swash M., and de Carvalho M. The Neurophysiological Index in ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 5 (2004) 108-110
128. Jokic N., de Aguilar J.G., Pradat P.F., et al. Nogo expression in muscle correlates with amyotrophic lateral sclerosis severity. Ann Neurol 57 (2005) 553-556
129. Pradat P.F., Bruneteau G., de Aguilar J.G., et al. Muscle Nogo-A expression is a prognostic marker in lower motor neuron syndromes. Ann Neurol 62 (2007) 15-20
130. Askanas V., Wojcik S., and Engel W.K. Expression of Nogo-A in human muscle fibers is not specific for amyotrophic lateral sclerosis. Ann Neurol 62 (2007) 676-677
131. Turner M.R., Bakker M., Sham P., Shaw C.E., Leigh P.N., and Al-Chalabi A. Prognostic modelling of therapeutic interventions in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 3 (2002) 15-21